Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.62 USD

0.62
108,359

-0.02 (-2.78%)

Updated May 20, 2024 03:59 PM ET

After-Market: $0.62 0.00 (-0.35%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 101 - 120 ( 203 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 101

01/25/2016

Company Report

Pages: 6

Important Visibility In Hand for BL-7010; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 102

01/13/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 103

01/12/2016

Company Report

Pages: 4

BL-8040 and Keytruda Team Up for an Intriguing Match; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 104

12/07/2015

Company Report

Pages: 11

ASH Data Drives Continued Momentum for ''8040

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 105

12/07/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 106

12/04/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 107

12/03/2015

Company Report

Pages: 7

Investor Day; ''8040''s Oncology Potential and Mozobil Differentiation

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 108

11/17/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 109

11/16/2015

Company Report

Pages: 6

3Q15 Results; ''8040 Continues to be Center of Focus

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 110

11/05/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 111

11/05/2015

Company Report

Pages: 7

After the Wait, ''8040 Delivers; More at ASH; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 112

10/26/2015

Industry Report

Pages: 11

Healthcare - Focusing on Value Creating Catalysts for Our CoverageThis report contains brief updates on the following: ADRO, AGTC, APHB, APTO, ARGS, BLRX, CFRX, CNCE, CYTK, CYTX, IMNP, PTN, STML, T.TST. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 113

08/21/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 114

08/20/2015

Company Report

Pages: 6

2Q15 Results; ''8040 Main Driver Backed by Pipeline

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 115

08/18/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 116

08/17/2015

Daily Note

Pages: 4

BL-8040 Program Marches On With New Study; AML PhII Topline Data Coming

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 117

07/28/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 118

07/27/2015

Company Report

Pages: 6

Bellerophon Gets Dinged; Focus Remains on ''8040; Target Lowered to $7

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 119

07/16/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 120

07/15/2015

Company Report

Pages: 7

PRESERVATION - Data Soon; Should Serve as Proxy for Upcoming U.S. Study

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party